Eton Pharmaceuticals, Inc. (ETON) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29772L1089
Eton Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 79.95 m USD |
| Gross profit | 42.74 m USD |
| Operating income | -844,000.00 USD |
| EBIT | 223,000.00 USD |
| Net income | -4.60 m USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
More stocks
- Shanghai Zijiang Enterprise Group Co Ltd (600210.SS)
- Afry AB (AFRY.ST)
- Digiwin Software Co Ltd (300378.SZ)
- Quantum Computing Inc. (QUBT)
- Neutron Holdings, Inc. Common Stock (LIME)
- TheRealReal, Inc. (REAL)
- Richelieu Hardware Ltd. (RCH.TO)
- MILLERKNOLL, INC. (MLKN)
- Fevertree Drinks PLC (FEVR.L)
- Suzhou Recodeal Interconnect System Co Ltd (688800.SS)
- Century Communities, Inc. (CCS)
- Perella Weinberg Partners (PWP)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.